Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in SLE with Refractory Thrombocytopenia
NCT05929248Phase 2Unknown
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of telitacicept in systemic lupus erythematosus (SLE). Status: unknown.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05929248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929248.